Dual Vectors Expressing Murine Factor VIII Result in Sustained Correction of Hemophilia A Mice
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Hemophilia A is a sex-linked disorder that results from a deficiency of functional factor VIII and is currently treated by protein replacement therapies. Within the past decade, gene therapy efforts have come to the forefront of novel therapeutics. In this work, a dual-vector approach was employed in which recombinant adeno-associated viral (rAAV) vectors expressing the heavy and light chains of the murine factor VIII gene were delivered either intramuscularly or intravenously to a mouse model of hemophilia A. From in vitro work, it was determined that coinfection with both vectors is required as heterodimerization of the heavy and light chains occurs intracellularly. In vivo, therapeutic levels of factor VIII expression were achieved throughout the duration of the study (22 weeks). Intravenous and intramuscular delivery resulted in a maximal average expression of 31.4 +/- 6.4 and 29 +/- 6.5% of normal murine factor VIII levels, respectively. Western blots of cryoprecipitate as well as immunostaining of injection sites with an anti-murine factor VIII light chain antibody also confirmed the expression of factor VIII. Because the murine form of the gene was used in the mouse model, less than 1 Bethesda unit of inhibitors was noted. This work demonstrates the feasibility of using rAAV vectors for the long-term treatment of hemophilia A.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nakai, H., Yant, S. R., Storm, T. A., Fuess, S., Meuse, L., & Kay, M. A. (2001) · Journal of Virology · doi:10.1128/jvi.75.15.6969-6976.2001 · Cited by 478
Snyder, R. O., Miao, C., Meuse, L., Tubb, J., Donahue, B. A., Lin, H.-F., Stafford, D. W., Patel, S., Thompson, A. R., Nichols, T., et al. (1999) · Nature Medicine · doi:10.1038/4751 · Cited by 409
Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy
Yan, Z., Zhang, Y., Duan, D., & Engelhardt, J. F. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.12.6716 · Cited by 305
Biochemical, immunological, and in vivo functional characterization of B-domain-deleted factor VIII
Pittman, D., Alderman, E., Tomkinson, K., Wang, J., Giles, A., & Kaufman, R. (1993) · Blood · doi:10.1182/blood.v81.11.2925.2925 · Cited by 268
Overcoming adeno-associated virus vector size limitation through viral DNA heterodimerization
Sun, L., Li, J., & Xiao, X. (2000) · Nature Medicine · doi:10.1038/75087 · Cited by 267 · cited 1×
“Another approach involving a dual-vector strategy taking advantage of the head-to-tail concatemerization of rAAV vectors after entry into the host cell was investigated (Sun et al ., 2000; Yan et al ., 2000).”
Self-citationBurton, M., Nakai, H., Colosi, P., Cunningham, J., Mitchell, R., & Couto, L. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.22.12725 · Cited by 104
Gene therapy for the hemophilias
Kay, M. A., & High, K. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.18.9973 · Cited by 96 · cited 1×
“Gene therapy approaches may circumvent these problems, and as little as 2% of normal FVIII activity can result in therapeutic effects (Connelly et al., 1996; Kay and High, 1999).”
Expression of Human Factor VIII by Splicing between Dimerized AAV Vectors
Chao, H., Sun, L., Bruce, A., Xiao, X., & Walsh, C. E. (2002) · Molecular Therapy · doi:10.1006/mthe.2002.0607 · Cited by 75 · cited 1×
“A study by Chao et al . showed a maximum of 4% normal levels of human factor VIII in NOD/SCID mice, using this approach (Chao et al ., 2002).”
Self-citation
Cited by
Repetitive sequences in complex genomes: Structure and evolution
Jurka, J., Kapitonov, V. V., Kohany, O., & Jurka, M. V. (2007) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.8.080706.092416 · Cited by 331
Treatment of human disease by adeno-associated viral gene transfer
Warrington, K. H., & Herzog, R. W. (2006) · Human Genetics · doi:10.1007/s00439-006-0165-6 · Cited by 155
“3d) (Mah et al. 2003).”
Lange, A. M., Altynova, E. S., Nguyen, G. N., & Sabatino, D. E. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.64 · Cited by 78
Hu, C., & Lipshutz, G. S. (2012) · Gene Therapy · doi:10.1038/gt.2011.200 · Cited by 48
Metadata
- Authors
- Mah, C., Sarkar, R., Zolotukhin, I., Schleissing, M., Xiao, X., Kazazian, H. H., & Byrne, B. J.
- Venue
- Human Gene Therapy
- Publisher
- SAGE Publications
- Published
- 2003-01-15
- Volume
- 14
- Issue
- 2
- Pages
- 143-152
- ISSN
- 1043-0342 (ISSN-L)
- 1557-7422
- OpenAlex
- W1976700163
- Cited by
- 36
- References
- 8
- FWCI
- 1.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dual Vectors Expressing Murine Factor VIII Result in Sustained Correction of Hemophilia A Mice. https://app.cochat.ai/papers/10.1089/104303403321070838
- The paper
- Mah, C., Sarkar, R., Zolotukhin, I., Schleissing, M., Xiao, X., Kazazian, H. H., & Byrne, B. J. (2003). Dual Vectors Expressing Murine Factor VIII Result in Sustained Correction of Hemophilia A Mice. Human Gene Therapy. https://doi.org/10.1089/104303403321070838
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.